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ABSTRACT 
In the present study, we focus on the causes of a major cancer type contributing to the major deaths due to cancer across the world. Breast 
cancer which accounts for more than approximately 29 to 34% affected to women posing a major cause of death due to cancer.  In-situ 
carcinomas might arise in either ductal or lobular epithelium, but remain confined there, with no invasion of the underlying basement 
membrane that would constitute extension beyond epithelial boundaries. Approximately 29 to 34% of women with invasive breast cancer will 
die of their disease. This syndrome presents as skin changes resembling skin condition like redness, discoloration, or mild flaking of the nipple 
skin. As Paget's disease of the breast advances, symptoms may include skin tingling, itching, increased sensitivity, bur ning and pain. There may 
also be discharge from the nipple. Approximately half of women diagnosed with Paget's disease of the breast even have a lump within the 
breast. 
Keywords: Breast cancer, BRCA mutation, BRCA1, BRCA2. 
 
Article Info: Received 21 May 2019; Review Completed 29 June 2019;  Accepted 11 July 2019;  Available online 19 July 2019 
Cite this article as: 
Chandira MR, Prabakaran M, Jaykar B, Venkateswarlu BS, Palanisamy P, BRCA Mutation: A Review of Breast Cancer, 
Journal of Drug Delivery and Therapeutics. 2019; 9(4):750-758   http://dx.doi.org/10.22270/jddt.v9i4.3602            
*Address for Correspondence:   
R. Margret Chandira, M.Pharm., Ph.D., Department of Pharmaceutics, Vinayaka Mission’s College of Pharmacy, Yercaud 
Main Road, Kondappanaickenpatty, Salem (D.T), Tamil Nadu (State), Pin. Code: 636 008. Mobile. No: +91-94430-09862 
 
 
INTRODUCTION: 
Cancer is a group of disease involved in abnormal growth of 
cell with the potential spread to other parts of the body.1, 2 
Cancer when develops to normal cells in a particular part of 
the body begin to grow out of control. Cardio vascular 
disease is the first leading cause of death in the world and 
Cancer is the second leading cause of death in the world. 
Generally cancer cells are developed from normal cells due 
to damage of DNA. Most of the time when ever DNA was 
damaged, the body is able to repair it, unfortunately in 
cancer cells, damaged DNA is not repaired. People can also 
inherit damaged DNA from parents, which accounts for 
inherited cancers.3 
Breast cancer: 
Cancer that forms in tissues of the breast. It occurs in both 
men and women, although male breast cancer is rare than 
female breast cancer. Breast cancer commonly develops in 
lining of milk duct cells and the lobules that supply the ducts 
with milk. Cancers developing from the ducts are known 
as ductal carcinomas. Although the cancers developing from 
lobules are known as lobular carcinomas.4,5 Breast cancers 
are divided into two major types, in-situ carcinomas and 
invasive(or infiltrating) carcinomas. The in-situ type of 
carcinomas may arise in ductal or lobular epithelium, but 
remain confined there, with no invasion of the underlying 
basement membrane that would constitute extension 
beyond epithelial boundaries.6Approximately 29% to 34% of 
women with invasive breast cancer will die of their disease.7 
Signs and symptoms: 
Signs of breast cancer may include a tumor in the breast, 
mutation in breast, dimpling of the skin, fluid coming from 
the breast nipple, a newly inverted nipple, or a red patch of 
skin. Inflammatory breast cancer is a one type of breast 
cancer which can pose a actual diagnostic challenge. 
Symptoms may resemble a inflammation in breast and may 
include pain, itching, nipple inversion, swelling, warmth and 
redness throughout the breast, as well as an orange-peel 
texture to the skin referred to as peau d'orange.8Another 
reported symptom complex of breast cancer is Paget's 
disease of the breast. This syndrome presents as skin 
redness, discoloration or mild flaking of the nipple skin. As 
Paget's disease of the breast advances, symptoms may 
include burning, itching, enhanced the sensitivity, tingling, 
and pain. Approximately half of women’s are diagnosed with 
Paget's disease of the breast also has a tumor in the breast.9 
In rare cases, what initially appears as a fibroadenoma (hard, 
movable non-cancer lump) could in fact be a phyllodes 
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tumor. Phyllodes tumors are formed within the connective 
tissue of the breast and contain glandular as well as stromal 
tissue. Phyllode breast lumps are not staged in the usual 
sense; they are classified depends on their appearance under 
the microscope as benign, borderline, or 
malignant.10Occasionally, breast cancer presents 
as metastatic disease that is, cancer that has spread away the 
original organ. The symptoms caused by metastatic breast 
cancer depend on the location of metastasis. Common sites of 
metastasis include bone, liver, lung and brain.11 
Causes of breast cancer: 
Genetic causes; Family history has long been known to be a 
risk factor for breast carcinoma. Both maternal and paternal 
relatives are important. The risk is highest if the affected 
relative developed breast carcinoma at a young age, had 
carcinoma in both breasts or if she is a close relative. First-
degree relatives, (mother, sister, daughter) are most vital in 
estimating risk. Some second-degree relatives (grandmother, 
aunt) with breast cancer may increase risk. Breast cancer in 
a male increases the risk for all his close female relatives. 
BRCA1and BRCA2 are abnormal genes that, when inherited, 
markedly increase the risk of breast cancer to a lifetime risk 
estimated between 40 and 8S%. Women who have the 
BRCA1 gene tend to develop breast cancer at an early age.12 
Hormonal causes; Alteration in hormonal level may 
precipitate breast cancer. It could be attended by starting 
and stopping of periods (Menstrual Cycle), Pregnancy in 
early age, Hormonal replacement therapy, Use of oral pills, 
etc.13 
Life style and dietary cause; Sedentary life style, high 
dietary intake of fat obesity particularly in postmenopausal 
women may cause breast cancer. The use of alcohol is also 
another one cause of breast cancer. The risk increases with 
the amount of alcohol consumed. Women who consume two 
to five alcoholic beverages per day have a risk about one and 
a half times that of nondrinkers for the development of 
breast cancer.14,15 
Environmental cause; There is known to be a slight 
increase in risk in ladies who work with low doses of 
radiation over a long period of time-for example, X-ray 
technicians.14,15 
Pathophysiology:  
Breast cancer, like other cancers occurs because of an 
interaction between an environmental (external) factor and 
a genetically susceptible host. Mutations that can lead to 
breast cancer have been experimentally linked to estrogen 
exposure.16 Abnormal growth factor signaling in the 
interaction between stromal cells and epithelial cells can 
facilitate malignant cell growth.17,18 In breast adipose tissue, 
over expression of leptin leads to increased cell proliferation 
and cancer.19 
In the United States, 10% to 20% of people with breast 
cancer and ovarian cancer have a first- or second-degree 
relative with one of these diseases. The familial tendency to 
developed cancer is called hereditary breast–ovarian cancer 
syndrome. The best known of these, the BRCA mutations, 
confer a lifetime risk of breast cancer of between 60% and 
85% and a lifetime risk of ovarian cancer of between 15 and 
40 percent. Some mutations associated with cancer, such 
as BRCA1 and BRCA2, occur in mechanisms to correct errors 
in DNA. These mutations are either inherited or acquired 
after birth. Presumably, they allow further mutations, which 
allow uncontrolled division, lack of attachment, and 
metastasis to distant organs.20 However, there is strong 
evidence of residual risk variation that goes well beyond 
hereditary BRCA gene mutations between carrier families. 
This is caused by unobserved risk factors.21 This implicates 
environmental and other causes as triggers for breast 
cancers. The inherited mutation in BRCA1 or BRCA2 genes 
can interfere with repair of DNA cross links and DNA double 
strand breaks (known functions of the encoded 
protein).22These carcinogens cause DNA damage such as 
DNA cross links and double strand breaks that often require 
repairs by pathways containing BRCA1 and BRCA2.23,24Focus 
of this present review is to study about the breast cancer by 
gene mutations. 
MATERIAL AND METHODS:  
Initially, we searched papers using keywords like breast 
cancer, gene mutation, genetic causes and BRCA. 
Subsequently the papers are matched such word criteria 
were fully reviewed and their findings duly noted. 
BRCA Mutation:  
A BRCA mutation is a mutation in either of the BRCA1 and 
BRCA2 genes, these are tumor suppressor genes. Different 
types of mutations in these genes have been identified, some 
of these determined to be harmful, while others have no 
proven impact. Harmful mutations in these genes may 
produce a hereditary breast cancer syndrome in affected 
persons. Breast cancer cases in women Only 5-10% are 
reason to BRCA1 and BRCA2 mutations (with BRCA1 
mutations being slightly more than BRCA2 mutations), but 
the impact on women with the gene mutation is more 
profound.25 Women with harmful mutations in either 
BRCA1 or BRCA2 have a risk of breast cancer that is about 
five times the normal risk, and a risk of ovarian cancer that is 
about ten to thirty times normal.26 
Mutations can be inherited from either parent and may be 
passed through on to both sons and daughters. Each child of 
a genetic carrier, not regard to sex, has a 50% chance of 
inheriting the mutated gene from the parent who carries the 
mutation. As a result, half of the people with BRCA gene 
mutations are male, who would then pass the mutation on to 
50% of their offspring, male or female. The risk of BRCA-
related breast cancers for men with the mutation is higher 
than for other men, but still low.27 
The BRCA1 and BRCA2 genes are tumor suppressor genes 
pictured here on their respective chromosomes. BRCA1 has 
located in 17q21 or the q arm of Chromosome 17 at position 
21. BRCA2 has located in 13q12.3 or the q arm of 
Chromosome 13 at position 12.3. Both BRCA1 and BRCA2 
genes are produce proteins that help repair damaged DNA, 
keeping the genetic material of the cell stable. A damaged 
BRCA gene in either location can lead to increased the risk of 
cancer, particularly breast or ovarian in women. 
 
Fig. 1: Location of BRCA Gene 
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Survival impact: 28 
 
Fig. 2: Likelihood of a 25-year-old woman surviving to age 70 
A 25-year-old woman with no mutation in her BRCA genes 
has an 84% probability to reach at least the age of 70. Of 
those not surviving, eleven percentage die from either breast 
or ovarian cancer, and 89% from other cancers. Compared to 
that, a woman with a high-risk BRCA1 mutation, if she 
had carcinomas in breast tissues screening but no 
prophylactic medical or surgical intervention, would have 
only fifty nine percentage chance to reach age 70, twenty five 
percentage points lower than normal. Of those women not 
surviving, twenty six percentage would die of breast cancer, 
forty six percentage of ovarian cancer and twenty eight 
percentage of other causes.  
Women with high-risk BRCA2 mutations, with screening but 
with no prophylactic medical or surgical intervention, would 
have only seventy one percentage chance to reach age 70, 
thirteen percentage points lower than normal. Of those not 
surviving twenty one percentage would die of breast cancer, 
twenty five percentage of ovarian cancer and fifty four 
percentage of other causes. The likelihood of surviving to 
minimum age 70 can be improved by several medical 
interventions, notably prophylactic mastectomy and 
oophorectomy.  
Childbearing and fertility effects: 
The dilemma of whether or not to have children is a 
significant source of stress for women who learn of 
their BRCA mutations during their childbearing 
years.29There is likely little or no effect of a BRCA gene 
mutation on overall fertility,30although women with 
a BRCA mutation may be more likely to have primary ovarian 
insufficiency.31,32 BRCA mutation carriers may be more likely 
to give birth to girls than boys,33 however this observation 
has been attributed to ascertainment bias.34,35If both parents 
are carriers of a BRCA mutation, then pre-implantation 
genetic diagnosis is sometimes used to prevent the birth of a 
child with BRCA mutations. Inheriting two BRCA1 mutations 
(one from parent) has never been reported and is believed to 
be a lethal birth defect. Inheriting one BRCA1 mutation and 
one BRCA2 mutation have been reported occasionally; the 
child's risk for any given type of cancer is the higher risk of 
the two genes like BRCA1 and BRCA2. (e.g., the risk of 
ovarian cancer from BRCA1 gene and the risk of pancreatic 
cancer from BRCA2 gene). Inheriting two BRCA2 mutations 
produces Fanconi anemia. [36]:82-85 
Each pregnancy in genetically typical women is associated 
with a significant reduction in the mother's risk of 
developing carcinomas in breast tissues after age of 40.29 The 
young woman is at the time of her first birth and the more 
protection against breast cancer she receives. Breastfeeding 
for more than one year protects against breast cancer.[36]:113–
142 Pregnancy also protects against ovarian cancer in 
genetically typical women.29 
Although some studies have produced different results, 
women with BRCA mutations are generally not expected to 
receive these significant protective benefits.[36]:113–142 Current 
research is too limited and imprecise to permit calculation of 
specific risks.29 
However, the following general trends have been identified: 
 For women with a BRCA1 mutation, the woman's age 
when she first gives birth has no association with her 
risk of breast cancer. Childbearing provides no 
protection against breast cancer, unless the woman has 
five or more than five full-term pregnancies, at which 
point she receives only modest protection. Similar to 
genetically typical women, pregnancy protects against 
ovarian cancer in BRCA1 gene women. Breastfeeding 
for more than one year considerably protects against 
breast cancer.29This effect may be as high as 19% per 
year of breastfeeding, which is much higher than that 
seen among genetically typical women.37 The effect, if 
any, of long-term breastfeeding on ovarian cancer is 
unclear.29 
 For women with a BRCA2 mutation, each pregnancy is 
paradoxically associated with a statistically significant 
increase in the risk for breast cancer. Unlike genetically 
typical women or women with BRCA1 gene mutations, 
breastfeeding has no effect on either cancer in women 
with BRCA2 gene mutations. Limited and conflicting 
data suggest that, also unlike other women, pregnancy 
does not decrease the ovarian cancer risk significantly 
in women with a BRCA2 gene mutation and might 
increase it.29 
BRCA1: 
Breast cancer type 1 susceptibility protein is a protein that in 
humans is encoded by the BRCA1 gene.38 Orthologs are most 
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common in other mammalian species.39 BRCA1 is a 
human tumor suppressor gene40, 41(also known as 
a caretaker gene) and is responsible for repairing 
DNA.42BRCA1 combines with other tumor suppressors, DNA 
damage sensors and signal transducers to form a large multi-
subunit protein complex known as the BRCA1-associated 
genome surveillance complex (BASC).43 The BRCA1 protein 
associates with RNA polymerase II, and through the C-
terminal domain, also interacts with histone 
deacetylase complexes. The role of this protein is 
transcription, and DNA repair of double-strand DNA 
breaks44 ubiquitination, transcriptional regulation as well as 
other functions.45 
BRCA1 has 24 exons, including 2 non-translating exons, 
encoding a protein of 1863 amino acids, which is 
characterized by a zinc-binding RING finger domain at the 
amino terminus and BRCA1carboxyl-terminal (BRCT) 
domain at the carboxylterminus.BRCA1 is classified as a 
tumor suppressor geneand plays an important role in 
surveillance of cell cycle and repair of DNA damage. Evidence 
shows that BRCA1 is phosphorylated by the check point 
kinase ataxia telangiectasia mutated (ATM) protein after 
ionizing radiation.46 
Gene location: 
The human BRCA1 gene is located on the long (q) arm 
of chromosome 17 at region 2 band 1, from base 
pair41,196,312 to base pair 41,277,500 (Build 
GRCh37/hg19) 47
 
 
Fig. 3: BRCA1 Gene location (Human) 
 
Mutations and Cancer risk: 
Certain variations of the BRCA1 gene lead to an increased 
risk for breast cancer as part of a hereditary breast and 
ovarian cancer symptoms. Researchers have identified more 
than hundred  mutations in the BRCA1 gene, many of which 
are associated with an increased risk of cancer. Females with 
an abnormal BRCA1 or BRCA2 genes have up to an 80% risk 
of developing carcinomas in breast tissues by age 90; 
increased risk of developing ovarian cancer is about 55% for 
females with BRCA1 mutations and about 25% for females 
with BRCA2 mutations.48 
These mutations can be changes in a small number of 
DNA base pairs (the building-blocks of DNA), and can be 
identified with PCR and DNA sequencing. Some cases large 
segments of DNAs are rearranged. Those large segments, 
also called large rearrangements, can be a deletion of one or 
several exons in the gene. Classical methods for mutation 
detection (sequencing) are unable to reveal these types of 
mutation.49 Other methods have been proposed: 
traditional quantitative PCR,50 Multiplex Ligation-dependent 
Probe Amplification (MLPA),51 and Quantitative Multiplex 
PCR of Short Fluorescent Fragments (QMPSF).52 Newer 
methods have also been recently proposed: hetero-duplex 
analysis (HDA) by multi-capillary electrophoresis or also 
dedicated oligo-nucleotides array based on comparative 
genomic hybridization (array-CGH).53Some results suggest 
that hyper-methylation of the BRCA1 promoter, which has 
been reported in some cancers, could be considered as an 
inactivating mechanism for BRCA1 expression.54 
BRCA1 mRNA 3' UTR can be bound by an miRNA, Mir-17 
microRNA. It has been suggested that variations in this 
miRNA along with Mir-30 microRNA could confer 
susceptibility to breast cancer.55In addition to breast cancer, 
mutations in the BRCA1 gene also increase the risk 
of ovarian and prostate cancers. Moreover, precancerous 
lesions (dysplasia) within the Fallopian tube have been 
linked to BRCA1 mutations. Pathogenic mutations anywhere 
in a model pathway containing BRCA1 and BRCA2 greatly 
increase risks for a subset of leukemias and lymphomas.44 
Females who have inherited a defective BRCA1 or BRCA2 
gene are greatly elevated risk to develop breast and ovarian 
cancer. Their risk of developing breast and ovarian cancer is 
high, and specific to those cancers, that many mutation 
carriers choose to have prophylactic surgery. There has been 
more conjecture to explain such apparently striking tissue 
specificity. Major determinants of where BRCA1 and BRCA2 
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hereditary cancers occur are associated to tissue specificity 
of the cancer pathogen, the agent that causes chronic 
inflammation or the carcinogen. The target tissue may 
having the receptors for the pathogen, may become 
selectively exposed to an inflammatory process or 
carcinogen. An innate genomic deficit in a tumor suppressor 
gene impairs normal responses and exacerbates the 
susceptibility to disease in organ targets. This theory also 
fits data for several tumor suppressors beyond BRCA1 or 
BRCA2 genes. A major advantage of this model is that it 
suggests there may be some options in addition to 
prophylactic surgery.56 
Low expression of BRCA1 in breast and ovarian cancers: 
BRCA1 expression is reduced or undetectable in the majority 
of high grade, ductal breast cancers.57 It has long been noted 
that loss of BRCA1 activity, either by germ-line mutations or 
by down-regulation of gene expression, leads to tumor 
formation in specific target tissues. In particular, decreased 
BRCA1 expression contributes to both sporadic and 
inherited breast tumor progression.58 Reduced expression of 
BRCA1 is tumorigenic because it plays an important role in 
the repair of DNA damages, especially double-strand breaks, 
by the potentially error-free pathway of homologous 
recombination. Since cells that lack the BRCA1 protein tend 
to repair DNA damages by alternative more error-prone 
mechanisms, the reduction or silencing of this protein 
generates mutations and gross chromosomal 
rearrangements that can lead to progression to breast 
cancer.59 
Similarly BRCA1 gene expression is low in the majority 
(55%) of sporadic epithelial ovarian cancers 
(EOCs) wherever EOCs are the common ovarian type of 
cancer, representing approximately 90% of ovarian 
cancers.60 In serous ovarian carcinomas, a sub-category 
constituting about 2/3 of EOCs, low BRCA1 expression 
occurs in more than 50% of cases.61 
Mutation of BRCA1 in breast and ovarian cancer:  
Only about 3%–8% of all women with breast cancer carry a 
mutation in BRCA1 or BRCA2.62 Similarly, BRCA1 mutations 
are only seen in about 18% of ovarian cancers (13% 
germline mutations and 5% somatic mutations).63Thus, 
while BRCA1 expression is low in the majority of these 
cancers, BRCA1 mutation is not a major cause of reduced 
expression. 
BRCA1 promoter hypermethylation in breast and 
ovarian cancer: 
BRCA1 promoter hypermethylation was present in only 13% 
of unselected primary breast 
carcinomas.64 Similarly, BRCA1 promoter hypermethylation 
was present in only 5% to 15% of EOC cases.60 Thus, while 
BRCA1 expression is low in these cancers, BRCA1 promoter 
methylation is only a minor cause of reduced expression. 
BRCA2: 
BRCA2 are a human gene, it is made up of proteins, 
respectively. The official symbol (BRCA2, italic for the gene, 
non-italic for the protein) and the official name 
(originally breast cancer 2; currently BRCA2, DNA repair 
associated) are maintained by the HUGO Gene Nomenclature 
Committee (HGNC). One alternative symbol, FANCD1, 
recognizes its association with the FANC 
protein complex. Orthologs, styled BRCA2 gene and BRCA2 
gene are common in other mammalian species.65BRCA2 gene 
covers about 70kb of genomic sequence in 13q12, encoding 
a protein of 3418 amino acids. The coding region of BRCA2 is 
composed of 27 exons with a non-translating exon. However, 
the gene sequence of BRCA2 bears no obvious homology to 
any known gene including BRCA1, and the protein contains 
no defined functional domains.66BRCA2 can bind with 
BRCA1, participating in DNA damage response pathway 
associated with the activation of homologous recombination 
and double-strand break repair.67BRCA2 associated breast 
carcinomas are rarely that “basal-like” phenotype, but a 
subtype that has higher grade (usually Grade 2/3) than 
sporadic cage-matched controls (Breast Cancer Linkage 
Consortium,1997), and tend to be ER and progesterone 
receptor (PR) positive.68 
Gene location: 
The BRCA2 gene is located on the long (q) arm 
of chromosome 13 at position 12.3 (13q12.3).69 
 
 
Fig. 4: BRCA2 Gene location (Human) 
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Function:  
Although the structures of the BRCA1 and BRCA2 genes are 
very different, at least some functions are interconnected. 
The proteins made by both genes are essential for repairing 
damaged DNA (see Fig. 5 of recombinational repair steps). 
BRCA2 binds the single strand DNA and directly interacts 
with the recombinase RAD51 to stimulate strand invasion, a 
vital step of homologous recombination. The localization of 
RAD51 to the DNA double-strand break needs to the 
formation of the BRCA1-PALB2-BRCA2 complex. Function of 
PALB2 (Partner and localizer of BRCA2)70 can synergistically 
with a BRCA2 chimera (termed piccolo, or piBRCA2) to 
further promote strand invasion.71 These breaks can be 
caused by natural and medical radiation or any other 
environmental exposures, but also occur when chromosomes 
exchange genetic material during a special type of cell 
division that creates sperm and eggs (meiosis). Double 
strand breaks are also generated during repair of 
deoxyribonucleic acid (DNA) cross links. By repairing DNA, 
these proteins play a role in maintaining the stability of 
the human genome and prevent dangerous gene 
rearrangements that can lead to hematologic and other 
cancers. BRCA2 has been shown to possess a crucial role in 
protection from the MRE11-dependent nucleolytic 
degradation of the reversed forks that are forming 
during DNA replication fork stalling (caused by obstacles 
such as mutations, intercalating agents etc.).72 
BRCA2 expression in cancer: 
In eukaryotes, BRCA2 protein has a very important role in 
homologous recombinational repair. In humans and mice, 
BRCA2 genes are primarily mediates orderly assembly of 
RAD51 on single-stranded DNA, the form that is active for 
homologous pairing and strand invasion. BRCA2 also 
redirects RAD51 from double-stranded DNA and prevents 
dissociation from single-stranded DNA.73 
 In addition, the four paralogs of RAD51, consisting of 
RAD51B (RAD51L1), RAD51C (RAD51L2), RAD51D 
(RAD51L3), XRCC2form a complex called the BCDX2 complex 
(see Figure 5: Recombinational repair of DNA). This complex 
participates in RAD51 recruitment or stabilization at damage 
sites.74
 
 
Fig. 5: Recombinational repair of DNA 
 
The BCDX2 complex appears to act by facilitating the 
assembly or stability of the RAD51 nucleoprotein filament. 
RAD51 catalyses strand transfer between a broken sequence 
and its undamaged homologue to allow re-synthesis of the 
broken region. 
Many cancers have epigenetic deficiencies in various DNA 
repair genes (see Frequencies of epimutations in DNA repair 
genes in cancers). These repair deficiencies likely cause 
raised unrepaired DNA damages. The over-expression 
of BRCA2 seen in many cancers may reflect 
compensatory BRCA2 over-expression and increased 
homologous recombinational repair to at least partially deal 
with such excess DNA damages.75 
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Table No. 1: Germline mutations and founder effect of BRCA1 and BRCA276,77 
Population or subgroup BRCA1 mutations BRCA1 mutations 
African-Americans 943ins10, M1775R - 
Afrikaners E881X - 
Ashkenazi Jewish 185delAG, 188del11, 5382insC 6174delT 
Austrians 2795delA, C61G, 5382insC, Q1806stop - 
Belgians 2804delAA, IVS5+3A>G - 
Dutch Exon 2 deletion, exon 13 deletion, 2804delAA 5579insA 
Finns 3745delT, IVS11-2A>G 8555T>G, 999del5, IVS23-2A>G 
French 3600del11, G1710X - 
French Canadians C4446T 8765delAG, 3398delAAAAG 
Germans 5382insC, 4184del4 - 
Greeks 5382insC - 
Hungarians 300T>G, 5382insC, 185delAG 9326insA 
Icelanders - 999del5 
Italians 5083del19 8765delAG 
Japanese L63X, Q934X - 
Native North Americans 1510insG, 1506A>G - 
Northern Irish 2800delAA 6503delTT 
Norwegians 816delGT, 1135insA, 1675delA, 3347delAG - 
Pakistanis 2080insA, 3889delAG, 4184del4, 4284delAG, IVS14-1A>G 3337C>T 
Polish 300T>G, 5382insC, C61G, 4153delA - 
Russians 5382insC, 4153delA - 
Scottish 2800delAA 6503delTT 
Slovenians - IVS16-2A>G 
Spanish R71G 
3034delAAAC(codon936), 
9254del5 
Swedish Q563X, 3171ins5, 1201del11, 2594delC 4486delG 
 
CONCLUSSION: 
The review study presented in this article details about the 
breast cancer which accounts majorly for more than 29-
34%, of death cases amongst the women population. Mostly 
the gene mutation breast cancer is affected in women. 
BRCA1 gene mutation breast cancer is more affected than 
BRCA2. This BRCA2 gene mutation is not common but can be 
higher in specific populations. 
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